Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Mood stabilisers may leads to lower attrition Timing of outcome assessment: end of treatment (32 days to… compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Adherence to pharmacotherapy: number of people completing treatment · COPD
Single component intervention showed no clear difference in adherence to pharmacotherapy: number of people completing treatment compared with control (low certainty).
1 finding from 1 review
Depression: mean scores at end of treatment (Analysis 1.4) · people with stroke
1 finding from 1 review
Psychological distress post‐treatment · people with stroke
1 finding from 1 review
General health · people with stroke
1 finding from 1 review
Social activities: mean scores at end of treatment (Analysis 2.10) · people with stroke
1 finding from 1 review
Activities of daily living · people with stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (Analysis 1.14) · people with stroke
It is very uncertain whether psychological therapy changes adverse events: death ‐ at end of treatment (Analysis 2.16) compared with usual care and/or attention control (very low certainty).
1 finding from 1 review
Depression: meeting study criteria for depression at end of · people with stroke
It is very uncertain whether psychological therapy changes depression: meeting study criteria for depression at end of… compared with usual care and/or attention control (very low certainty).
1 finding from 1 review
Scoring above cut‐off points for a depressive disorder at end of treatment (Analysis 1.2) · people with stroke
1 finding from 1 review
Treatment cessation due to adverse events · CRRT
Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).
1 finding from 1 review